Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

AstraZeneca PLC (LON:AZN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine analysts that ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Berenberg Bank in a report issued on Monday, MarketBeat reports. They presently have a GBX 140 ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with an aggressive form of lung cancer. The drug has been specifically authorised ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase ...

AstraZeneca’s IMFINZI® On December 5, AstraZeneca announced that it gained another FDA-approved indication for its cancer drug IMFINZI® (durvalumab). IMFINZI® was approved for the treatment ...